India's indigenously manufactured Covid vaccine Covaxin, developed by Hyderabad-based Bharat Biotech (BB), will be delayed in its launch in the US market as the US Food and Drug Administration (FDA) asked Ocugen Inc, the US partner of BB, to pursue a biological Applications (BLA) path that would require additional clinical trials for the vaccine
